Skip to main content
Sarah Leary, MD, Pediatric Hematology & Oncology, Seattle, WA

Sarah E. Leary MD


Professor of Pediatrics, University of Washington School of Medicine

Join to View Full Profile
  • 4800 Sand Point Way NeMailstop B-6553Seattle, WA 98105

  • Phone+1 206-987-2106

  • Fax+1 206-987-3946

Dr. Leary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Tennessee
    University of TennesseeFellowship, Pediatric Hematology/Oncology, 2004 - 2007
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Pediatrics, 2001 - 2004
  • University of Tennessee Health Science Center College of Medicine
    University of Tennessee Health Science Center College of MedicineClass of 2001

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2009 - 2026
  • AK State Medical License
    AK State Medical License 2021 - 2022
  • DC State Medical License
    DC State Medical License 2007 - 2010
  • MD State Medical License
    MD State Medical License 2007 - 2010
  • VA State Medical License
    VA State Medical License 2007 - 2010
  • TN State Medical License
    TN State Medical License 2004 - 2008
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Heterogeneity Within the PF-EPN-B Ependymoma Subgroup  
    Andrew Grossbach, Vijay Ramaswamy, Benjamin Lu, Mariarita Santi, Caterina Giannini, Linda M Liau, Terri S Armstrong, Sarah Leary, Matthias A Karajannis, Kenneth Aldape..., Acta Neuropathologica

Press Mentions

  • Blaze Bioscience Announces Enrollment Is Complete on Its Pivotal Phase 2/3 Trial of Tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System Tumors
    Blaze Bioscience Announces Enrollment Is Complete on Its Pivotal Phase 2/3 Trial of Tozuleristide and the CanvasTM Imaging System in Pediatric Central Nervous System TumorsNovember 2nd, 2022
  • New Grant Enables Further Testing of Reliable, Non-Invasive Pediatric Brain Cancer Platform
    New Grant Enables Further Testing of Reliable, Non-Invasive Pediatric Brain Cancer PlatformOctober 31st, 2022
  • Seattle Children’s Research Division: Celebrating 15 Years of Innovation
    Seattle Children’s Research Division: Celebrating 15 Years of InnovationNovember 12th, 2021
  • Join now to see all

Grant Support

  • Pediatric brain tumors: Improving survival through integration of clinical molecular diagnostics and biologically targeted therapies into clinical trialsSEATTLE CHILDREN'S HOSPITAL2023–2028
  • Pediatric brain tumors: Improving survival through integration of clinical molecular diagnostics and biologically targeted therapies into clinical trialsSEATTLE CHILDREN'S HOSPITAL2023–2028

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: